Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...

IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

Patients with  a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, the largest ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...